Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Gilead Sciences snares Roche veteran O'Day as CEO

share with twitter share with LinkedIn share with facebook
share via e-mail
12/10/2018 | 05:00am EST
Roche Pharmaceuticals CEO O'Day attends a news conference in Basel

(Reuters) - Drugmaker Gilead Sciences Inc on Monday named Roche Holding AG's Daniel O'Day as its new chief executive, tapping an industry veteran to fill a management vacuum.

O'Day, now head of Roche's pharmaceuticals business, joined the company in 1987 and held various roles in the United States before moving in 1998 to headquarters in Basel, Switzerland.

O'Day's hiring comes about four months after Gilead said in July that Chief Executive John Milligan and Chairman John Martin would step down at the end of the year.

Jefferies analysts said in a note that O'Day's three decades of oncology and global commercial expertise at Roche should help Gilead build out its own global presence, particularly in new areas it is entering including oncology and inflammation as well as through more acquisitions and in-licensing deals.

At Roche, O'Day was a champion of bi-specific antibodies that are under development as a potentially less expensive, less complicated alternative to CAR-T therapy where T cells must be taken out of the body, re-engineered and re-infused.

With Gilead's Yescarta therapy, O'Day is now on the opposite side of the divide.

Separately, Roche said William Anderson, current CEO of its Genentech business, would replace O'Day next year.

Anderson joined Roche in 2006, leading the immunology business unit in Genentech, and then took charge of oncology sales and marketing. In 2013, he became head of global product strategy based in Basel before assuming his current role at Genentech in 2017.

Vontobel analyst Stefan Schneider called Anderson a "seasoned Roche manager" who played a key role in leading multiple sclerosis drug Ocrevus to success and driving double-digit growth in the U.S. market.

Gilead said on Monday that Martin would step down from the company's board of directors, effective March 1, 2019.

Up to Friday's close, the company's shares have fallen nearly 14 percent since Milligan and Martin's departures were announced by Gilead in July.

The Wall street Journal first reported O'Day's hiring on Sunday.

Gilead said its board had appointed Gregg Alton as interim chief executive for the period of January 1, 2019 until O'Day's start date of March 1, 2019.

Roche shares were down 0.6 percent by mid-morning, in line with the Stoxx European health care sector index <.SXDP>.

(Reporting by Liana Baker in New York; Additional reporting by Ismail Shakil and Philip George in Bengaluru and by John Miller and Michael Shields in Zurich; Editing by Sunil Nair and Mark Potter)

Stocks mentioned in the article
ChangeLast1st jan.
FORBO HOLDING AG -0.25% 1592 Delayed Quote.15.13%
GILEAD SCIENCES -1.13% 64.64 Delayed Quote.3.34%
ROCHE HOLDING AG -0.25% 297.25 Delayed Quote.22.19%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on ROCHE HOLDING AG
11/11CHUGAI PHARMACEUTICAL : Files a New Drug Application for Satralizumab for NMOSD ..
11/11ROCHE : Genentech's Gazyva in Combination With Standard of Care, More Than Doubl..
11/11PTC THERAPEUTICS : Risdiplam Pivotal SUNFISH Study Demonstrates Statistically Si..
11/11Roche's Gazyva (obinutuzumab), in combination with standard of care, more tha..
11/11GENENTECH : 's Risdiplam Meets Primary Endpoint in Pivotal SUNFISH Trial in Peop..
11/11Roche's risdiplam meets primary endpoint in pivotal SUNFISH trial in people w..
11/09GENENTECH : 's Gazyva (obinutuzumab), in Combination With Standard of Care, More..
11/07HARMONY® TEST : The first non-invasive prenatal test approved by Health Canada
11/06GENENTECH : to Present New Data Highlighting Breadth of Hematology Portfolio and..
11/06Roche to present new data highlighting breadth of haematology portfolio and p..
More news
Financials (CHF)
Sales 2019 61 835 M
EBIT 2019 22 068 M
Net income 2019 14 578 M
Debt 2019 2 632 M
Yield 2019 3,09%
P/E ratio 2019 17,9x
P/E ratio 2020 17,1x
EV / Sales2019 4,13x
EV / Sales2020 3,94x
Capitalization 253 B
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 311,68  CHF
Last Close Price 295,90  CHF
Spread / Highest target 20,3%
Spread / Average Target 5,33%
Spread / Lowest Target -24,0%
EPS Revisions
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG22.19%254 722
JOHNSON & JOHNSON3.06%344 670
PFIZER-15.40%208 023
NOVARTIS17.78%198 320
NOVO NORDISK AS30.58%133 015